Dupilumab and Alopecia Areata: A Possible Combined or Disturbance Therapy? A Review of The Literature.

Autor:	Starace M; Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola-Malpighi, Bologna, Italy.; Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Italy., Cedirian S; Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola-Malpighi, Bologna, Italy.; Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Italy., Quadrelli F; Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola-Malpighi, Bologna, Italy.; Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Italy., Pampaloni F; Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola-Malpighi, Bologna, Italy.; Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Italy., Brunetti T; Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola-Malpighi, Bologna, Italy.; Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Italy., Chessa MA; Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola-Malpighi, Bologna, Italy.; Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Italy., Gurioli C; Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola-Malpighi, Bologna, Italy., Piraccini BM; Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola-Malpighi, Bologna, Italy.; Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Italy., Neri I; Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola-Malpighi, Bologna, Italy.
Jazyk:	angličtina
Zdroj:	Dermatology practical & conceptual [Dermatol Pract Concept] 2024 Oct 30; Vol. 14 (4). Date of Electronic Publication: 2024 Oct 30.
DOI:	10.5826/dpc.1404a270
Abstrakt:	Introduction: Dupilumab, a monoclonal antibody targeting IL-4 receptor subunit alpha, treats atopic dermatitis (AD) and may impact alopecia areata (AA). AA involves Th1-driven immune activity, and recent studies suggest a role for Th2 pathways. Dupilumab's effects on AA are mixed, with reports of both improvement and worsening. Objectives: This study aims to review the effects of dupilumab on AA in patients with AD, analyzing literature to understand cases of improvement or worsening and identifying contributing factors. Methods: A literature review was conducted using articles in platforms such as PubMed, Scopus, and Web of Science written up to April 2024, focusing on studies involving AA, AD, and dupilumab. Articles were analyzed for patient demographics, disease characteristics, and responses to treatment. Results: Out of 35 articles reviewed, 13 AA cases worsened after dupilumab (mean age 32.8; mostly males with patchy alopecia), and 38 cases showed improvement (mean age 27.6; majority females, varying AA types). Full hair regrowth occurred in 11 improved cases, while 9 had partial regrowth. Conclusions: Dupilumab shows dual effects on AA, influenced by Th1/Th2 immune profiles. Worsening was more common in males with Th1-driven AA, while females with Th2-skewed AA saw improvement. Factors like age, disease severity, and IgE levels may affect outcomes, suggesting a need for personalized treatment approaches for AA patients with AD.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu